Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out

J Clin Oncol. 2025 Jan 10;43(2):122-124. doi: 10.1200/JCO-24-01572. Epub 2024 Oct 7.

Abstract

This comment discusses the use of PD-L1 as a biomarker to guide treatment decisions for metastatic melanoma.

MeSH terms

  • B7-H1 Antigen* / antagonists & inhibitors
  • B7-H1 Antigen* / metabolism
  • Biomarkers, Tumor* / metabolism
  • Humans
  • Immune Checkpoint Inhibitors* / therapeutic use
  • Melanoma* / drug therapy
  • Melanoma* / immunology
  • Melanoma* / metabolism
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / genetics
  • Skin Neoplasms / immunology
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / pathology

Substances

  • B7-H1 Antigen
  • Immune Checkpoint Inhibitors
  • CD274 protein, human
  • Biomarkers, Tumor